Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer

Biochemical Pharmacology

Volumn 80, Issue 12, 2010, Pages 1921-1929

  Mehta, Kapil ^a   Kumar, Aupam ^a   Kim, Hong Im ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer stem cell; Drug resistance; Epithelial to mesenchymal transition; Inflammation; Metastasis

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DIETHYLCARBAMAZINE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL INVASION; CELL SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INFLAMMATION; INVASIVE CARCINOMA; NEOPLASM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE THERAPY; GTP-BINDING PROTEINS; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; RNA, SMALL INTERFERING; TRANSGLUTAMINASES;

EID: 78049427740     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.029     Document Type: Review

References (91)

1. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156.
2. Mehta K. Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 2005, 38:1-18.
3. Nakaoka H., Perez D.M., Baek K.J., Das T., Husain A., Misono K., et al. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 1994, 264:1593-1596.
4. Hasegawa G., Suwa M., Ichikawa Y., Ohtsuka T., Kumagai S., Kikuchi M., et al. A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 2003, 373:793-803.
5. Mishra S., Murphy L.J. Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 2004, 279:23863-23868.
6. Mhaouty-Kodja S. Gha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 2004, 96:363-367.
7. Fesus L., Madi A., Balajthy Z., Nemes Z., Szondy Z. Transglutaminase induction by various cell death and apoptosis pathways. Experientia 1996, 52:942-949.
8. Nicholas B., Smerthurst P., Verderio E., Jones R., Griffin M. Crosslinking of cellular proteins by tissue transglutaminase during nectrotic cell death: mechanism for maintaining tissue integrity. Biochem J 2003, 371:413-422.
9. Chhabra A., Verma A., Mehta K. Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res 2009, 29:1909-1920.
10. Kim D.S., Park S.S., Nam B.H., Kim I.H., Kim S.Y. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 2006, 66:10936-10943.
11. Verma A., Mehta K. Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 2007, 7:559-565.
12. Nanda N., Iismaa S.E., Dagger, Owens W.A., Husain A., Mackay F. Graham RM targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001, 276:20673-20678.
13. Verderio E.A.M., Johnson T.S., Griffin M. Transglutaminases in wound healing and inflammation. Transglutaminases family of enzymes with diverse functions 2005, 89-114. Karger AG, Basel. K. Mehta, R. Eckert (Eds.).
14. Iismaa S.E., Mearns B.M., Lorand L., Graham R.M. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009, 89:991-1023.
15. Verderio E.A.M., Johnson T., Griffin M. Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids 2004, 26:387-404.
16. Quan G., Choi J.Y., Lee D.S., Lee S.C. TGF-beta1 upregulates transglutaminase 2 and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch Dermatol Res 2005, 297:84-90.
17. Kuncio G.S., Tsyganskaya M., Zhu J., Liu S.-L., Nagy L., Thomazy V., et al. TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells. Am J Physiol 1998, 274:G240-G245.
18. Kim S.Y. Transglutaminase 2 in inflammation. Front Biosci 2006, 11:3026-3035.
19. Johnson K., Hashimoto S., Lotz M., Pritzker K., Terkeltaub R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 2001, 159:149-163.
20. Suto N., Ikura K., Sasaki R. Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells. J Biol Chem 1993, 268(10):7469-7473.
21. Haroon Z.A., Hettasch J.M., Lai TSDewhirst M.W., Greenberg C.S. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 1999, 13(13):1787-1795.
22. Falasca L., Farrace M.G., Rinaldi A., Tuosto L., Melino G., Piacentini M. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J Immunol 2008, 180:2616-2624.
23. Nardacci R., Lo Iacono O., Ciccosanti F., Falasca L., Addesso M., Amendola A., et al. Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol 2003, 162:1293-1303.
24. Tatsukawa H., Kojima S. Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis. Cell Biol Int 2010, 34:325-334.
25. Shweke N., Boulos N., Jouanneau C., Vandermeersch S., Melino G., Dussaule J.C., et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 2008, 173:631-642.
26. Seiving B., Ohlsson K., Linder C., Stenberg P. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. Eur J Haematol 1991, 46:263-271.
27. Garabuczi E., Sarang Z., Vereb G., Vámosi G., Aeschlimann D., Blaskó B., et al. Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol 2009, 182:2084-2092.
28. Akimov S.S., Belkin A.M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 2001, 98(5):1567-1576.
29. Gross S.R., Balklava Z., Griffin M. Importance of tissue transglutaminase in repair of extracellular matrices and cell death of dermal fibroblasts after exposure to a solarium ultraviolet A source. J Invest Dermatol 2003, 121:412-423.
30. Akimov S.S., Krylov D., Fleischman L.F., Belkin A.M. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 2000, 148:825-838.
31. Telci D., Wang Z., Li X., Verderio E.A., Humphries M.J., Baccarini M., et al. Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and beta1 integrin co-signaling. J Biol Chem 2008, 283:20937-20947.
32. Xu L., Begum S., Hearn J.D., Hynes R.O. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 2006, 103:9023-9028.
33. Grivennikov S., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
34. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer related inflammation. Nature 2008, 454:436-444.
35. Verma A., Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 2007, 10:144-151.
36. Mangala L.S., Fok J.Y., Zorrilla-Calancha I.R., Verma A., Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470.
37. Ai L., Kim W.J., Demircan B., Dyer L.M., Bray K.J., Skehan R.R., et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 2008, 29:510-518.
38. Verma A., Wang H., Manavathi B., Fok J.Y., Mann A.P., Kumar R., et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006, 66:10525-10533.
39. Mehta K., Fok J., Miller F.R., Koul D., Sahin A.A. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004, 10:8068-8076.
40. Fok J.Y., Ekmekcioglu S., Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006, 5:1493-1503.
41. Hwang J.Y., Mangala L.S., Fok J.Y., Lin Y.G., Merritt W.M., Spannuth W.A., et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68:5849-5858.
42. Satpathy M., Cao L., Pincheira R., Emerson R., Bigsby R., Nakshatri H., et al. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 2007, 67:7194-7202.
43. Park K.S., Kim H.K., Lee J.H., Choi Y.B., Park S.Y., Yang S.H., et al. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:493-502.
44. Yuan L., Siegel M., Choi K., Khosla C., Miller C.R., Jackson E.N., et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007, 26:2563-2573.
45. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003, 63:8614-8622.
46. Jiang D., Ying W., Lu Y., Wan J., Zhai Y., Liu W., et al. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 2003, 3:724-737.
47. Antonyak M.A., Miller A.M., Jansen J.M., Boehm J.E., Balkman C.E., Wakshlag J.J., et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 2004, 279:41461-41467.
48. Verma A., Guha S., Diagaradjane P., Kunnumakkara A.B., Sanguino A.M., Lopez-Berestein G., et al. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 2008, 14:2476-2483.
49. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
50. Khera V., Mehta K. Transglutaminase levels and immunologic functions of BCG-elicited mouse peritoneal macrophages isolated by centrifugal elutriation. J Leukoc Biol 1989, 45:434-443.
51. Mohan K., Pinto D., Issekutz T.B. Identification of tissue transglutaminase as a novel molecule involved in human CD8+ T cell transendothelial migration. J Immunol 2003, 171:3179-3186.
52. Priglinger S.G., Alge C.S., Neubauer A.S., Kristin N., Hirneiss C., Eibl K., et al. TGFb-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. Invest Ophthal Visual Sci 2004, 45:955-963.
53. Joshi S., Guleria R., Pan J., DiPette D., Singh U.S. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006, 25:240-247.
54. Song H., Chang W., Lim S., Seo H.S., Shim C.Y., Park S., et al. Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells 2007, 25:1431-1438.
55. Nguyen D.X., Bos P.D., Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
56. Chen G., Gharib T.G., Huang C.C., Thomas D.G., Shedden K.A., Taylor J.M., et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002, 8:2298-2305.
57. Kong L., Korthuis R.J. Melanoma cell adhesion to injured arterioles: mechanisms of stabilized tethering. Clin Exp Metastasis 1997, 15:426-431.
58. Xu L., Hynes R.O. GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment. Cell Cycle 2007, 6:160-165.
59. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
60. Bertout J., Thomas-Tikhonenko A. Infection & neoplastic growth 101: the required reading for microbial pathogens aspiring to cause cancer. Cancer Treat Res 2006, 130:167-197.
61. Thiery P.J., Acloque H., Huang R.Y.J., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-887.
62. López-Novoa J.M., Nieto M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009, 1:303-314.
63. Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27:6920-6929.
64. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesechymal transitions. J Clin Invest 2009, 119:1429-1437.
65. Nieman M.T., Prudoff R.S., Johnson K.R., Wheelock M.J. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999, 147:631-644.
66. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119:1417-1419.
67. Xu J., Lamouille S. Derynck R.TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19:156-172.
68. Wendt M.K., Allington T.M., Schiemann W.P. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 2009, 5:1145-1168.
69. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B: Phys Biol Sci 2009, 85:314-323.
70. Sarkar F.H., Li Y., Wang Z., Kong D. Pancreatic cancer stem cell and EMT in drug resistance and metastasis. Minerva Chir 2009, 64:489-500.
71. Boutet A., De Frutos C.A., Maxwell P.H., Mayol M.J., Romero J., Nieto M.A. Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J 2006, 25:5603-5613.
72. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
73. Shao M., Cao L., Shen C., Satpathy M., Chelladurai B., Bigsby R.M., et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 2009, 69:9192-9201.
74. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
75. Verderio E.A., Telci D., Okoye A., Melino G., Griffin M. A novel RGD-independent cel adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J Biol Chem 2003, 278:42604-42614.
76. Verma A., Guha S., Wang H., Fok J.Y., Koul D., Abbruzzese J., et al. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 2008, 14:1997-2005.
77. Herman J.F., Mehta K. Implications of increased tissue transglutaminase expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 2006, 25:3049-3058.
78. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
79. Margit D., Huber A., Azoitei N., Baumann B., Grunert S., et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004, 114:5669-5681.
80. Karin M., Cao Y., Greten F.R., Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
81. Orlowski R.Z., Baldwin A.S. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002, 8:385-389.
82. Wu Y., Deng J., Rychahou P.G., Qui S., Evers B.M., Zhou B.P. Stabilization of Sanil by NF-kB is required for inflammation-induced cell migration and invasion. Cell 2009, 15:416-428.
83. Chua H.L., Bhat-Nakshatri P., Clare S.E., Morimiya A., Badve S., Nakshat NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007, 26:711-724.
84. Kim Y., Eom S., Kim K., Lee Y.S., Choe J., et al. Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation. Mol Immunol 2010, 47:1010-1022.
85. Ritter S.J., Davies P.J. Identification of a transforming growth factor-beta1/bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter. J Biol Chem 1998, 273:12798-12806.
86. Nunes I., Gleizes P.E., Metz C.N., Rifkin D.B. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997, 136:1151-1163.
87. Telci D., Collighan R.J., Basaga H., Griffin M. Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. J Biol Chem 2009, 284:29547-29558.
88. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
89. Cao L., Petrusca D.N., Satpathy M., Nakshatri H., Petrache I., Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008, 29:1893-1900.
90. Yuan L., Choi K., Khosla C., Zheng X., Higashikubo R., Chicoine M.R., et al. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 2005, 4:1293-1302.
91. Zemskov E.A., Loukinova E., Mikhailenko I., Coleman R.A., Strickland D.K., Belkin A.M. Regulation of platelet-derived growth factor receptor function by integrin-associated cell surface transglutaminase. J Biol Chem 2009, 284:16693-16703.